DNSP-11: proGDNF-Derived Dopaminergic Neuropeptide, ERK1/2-Mediated Neuronal Survival, and Dopamine System Restoration in Parkinson's Disease Research Models
<h2Abstract & Overview</h2 <pDopamine Neuron Stimulating Peptide11 (DNSP11; sequence: PPEAPAEDRSLNH₂; MW 1.2 kDa) is a synthetic 11aminoacid Cterminally amidated peptide derived from the proprotein region of human glial cell linederived neurotrophic factor (GDNF). Originally characterised by Bradley et al. at the University of Kentucky in 2010, DNSP11 was identified through a posttranslational processing model of the human GDNF proprotein that predicts the liberation of an 11mer amidated peptide from the proregion through a series of endoproteolytic cleavage events at flanking dibasic sites, followed by Cterminal amidation [1]. The rat homolog of DNSP11 (LLEAPAEDHSLNH₂), independently identified as Brain Excitatory Peptide (BEP) by Immonen et al., was found to exhibit binding affinity for CNS tissues and to increase excitatory postsynaptic potentials in hippocampal brain slices, providing independent validation of the biological activity of this proGDNFderived sequence [1][2].</p <pDNSP11 exhibits potent neurotrophic and neuroprotective actions in dopaminergic neuronal systems, supporting the survival of fetal mesencephalic neurons, protecting against 6hydroxydopamine (6OHDA)induced cell death in dopaminergic cell lines, and increasing dopamine (DA) and dopamine metabolite tissue levels in the substantia nigra of rodent Parkinson's disease (PD) models for up to 28 days following a single treatment. Critically, DNSP11 does not appear to signal through the canonical GFRα1/RET receptor complex utilised by mature GDNF, but instead activates the ERK1/2 (MAPK) prosurvival pathway — a mechanistic distinction that may underlie its effectiveness in severe lesion models where GDNF itself fails to produce biological effects [3][4]. The compound's small molecular size (1.2 kDa vs. 134 aa for mature GDNF), absence of heparinbinding domains, and validated efficacy following noninvasive intranasal administration collectively position DNSP11 as a compelling GDNF mimetic candidate for Parkinson's disease research with significant translational advantages over the parent neurotrophic factor [5][6].</p <blockquote"Here we present that DNSP11 exhibits potent neurotrophic actions analogous to mature GDNF, making it a viable candidate for a PD therapeutic. However, it likely signals through pathways that do not directly involve the GFRα1 receptor. These data strongly support that the propeptides of GDNF, and other neurotrophic factors, may have novel, longoverlooked physiological and potentially therapeutic functions." — Bradley et al. PLOS ONE. 2010;5(3):e9752 [1].</blockquote <h2Molecular Identity and Structural Architecture</h2 <h3GDNF Proprotein Origin and Endoproteolytic Liberation</h3 <pTo understand DNSP11's structural origin, it is necessary to appreciate the biosynthetic processing of GDNF. GDNF is endogenously produced as a 211aminoacid preproprotein. Following signal peptidase cleavage of the Nterminal 19aminoacid presequence, the resulting proGDNF undergoes further proteolytic processing to yield the biologically active mature GDNF protein (approximately 134 amino acids in its processed form). Examination of the human GDNF prosequence by Bradley et al. and Immonen et al. independently predicted the presence of internal dibasic endopeptidase cleavage sites flanking an 11aminoacid sequence within the proregion. Endoproteolytic cleavage at these dibasic sites, followed by Cterminal amidation by peptidylglycine αamidating monooxygenase (PAM), would theoretically yield the 11mer amidated peptide PPEAPAEDRSLNH₂, designated DNSP11 [1].</p <pThe predicted processing scheme is supported by endogenous immunostaining data. Using a polyclonal antibody raised against the DNSP11 sequence, Bradley et al. (2010) demonstrated that DNSP11 immunoreactivity is present in the perikaryal cytoplasm of tyrosine hydroxylase positive (TH+) dopaminergic neurons in the substantia nigra of rat pups at postnatal day 10 (PN10), colocalising with GDNF immunoreactivity at this developmental time point. Notably, DNSP11like immunoreactivity was also detected in the olfactory bulb, hippocampal granule cells, cerebellar granule cells, and the locus coeruleus — a region where GDNF is not expressed. This differential spatial distribution from mature GDNF strongly suggests that the DNSP11 sequence serves an independent biological function beyond its role as a structural component of the GDNF proprotein [1][6].</p <h3Sequence Characteristics and Physicochemical Properties</h3 <pThe human DNSP11 sequence (PPEAPAEDRSLNH₂) is an 11aminoacid linear peptide with a Cterminal amide modification. The sequence contains two proline residues (P1 and P4) that confer conformational rigidity to the Nterminal region, an alaninerich central segment (A3, A5, A7) that provides structural flexibility, a negatively charged aspartate residue (D8) and arginine residue (R9) that contribute to the peptide's electrostatic properties, and a Cterminal serineleucineamide (SLNH₂) t
For research use only. Not for human consumption.